Last reviewed · How we verify
NCT04380064
Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy
NA trial testing ILM Peeling in Diabetic Retinopathy Visually Threatening in 200 participants. Status unknown.
1 February 2025
Quick facts
| Lead sponsor | Rush Eye Associates |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 May 2020 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2025 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- ILM Peeling
- No ILM Peeling
Conditions studied
- Diabetic Retinopathy Visually Threatening — all drugs for Diabetic Retinopathy Visually Threatening →
Sponsor
Rush Eye Associates
Who can join
Adults 18 to 85, any sex, with Diabetic Retinopathy Visually Threatening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Subject/Participant Groups: Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment Control Group: Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04380064
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ILM Peeling
Trials testing the same drug.
- NCT06063005 — Clinical Study of Translocated Internal Limiting Membrane Flap Reposition for the Treatment of Idiopathic Macular Hole · NA · unknown
- NCT02146144 — Prospective, Single-blind Study Assessing the Benefit/Risk Ratio of Internal Limiting Membrane (ILM) Peeling During Epim · NA · completed
Other recruiting trials for Diabetic Retinopathy Visually Threatening
Currently open trials in the same condition.
- NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting
Other Rush Eye Associates trials
Trials by the same sponsor.
- NCT04903301 — Patient Satisfaction With Contoura Vision Topography-Guided LASIK · NA · completed
- NCT04380077 — Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Diabetics · NA · unknown
- NCT03660345 — PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME · Phase 3 · completed
- NCT03660371 — ILM Peeling in PDR Patients Undergoing PPV for VH · NA · completed
- NCT03660384 — Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04380064 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rush Eye Associates
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04380064.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing